Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1849-Fab is a Fab fragment of a monoclonal antibody (1849) directed against human tissue factor (TF). Tissue factor is a transmembrane glycoprotein that is highly expressed in various malignancies, particularly pancreatic cancer, where it contributes to tumor growth, angiogenesis, and metastasis. As a Fab fragment, 1849-Fab lacks the Fc region of the whole IgG, resulting in a smaller molecular size that facilitates faster renal clearance, more rapid tumor accumulation, and improved penetration into the tumor microenvironment. Preclinical studies have investigated 1849-Fab as a diagnostic imaging tool, demonstrating its ability to provide high-contrast signals for the early detection and localization of TF-overexpressing tumors when conjugated to fluorescent markers such as Alexa Fluor 647.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1849-Fab.